CYCLACEL PHARMACEUTICALS INC (CYCC) Fundamental Analysis & Valuation

NASDAQ:CYCC • US23254L8019

6.365 USD
-0.4 (-5.98%)
At close: Sep 11, 2025
6.4 USD
+0.04 (+0.55%)
After Hours: 9/11/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CYCC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall CYCC gets a fundamental rating of 3 out of 10. We evaluated CYCC against 520 industry peers in the Biotechnology industry. CYCC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CYCC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. CYCC Profitability Analysis

1.1 Basic Checks

  • CYCC had negative earnings in the past year.
  • In the past year CYCC has reported a negative cash flow from operations.
  • CYCC had negative earnings in each of the past 5 years.
  • CYCC had a negative operating cash flow in each of the past 5 years.
CYCC Yearly Net Income VS EBIT VS OCF VS FCFCYCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • CYCC has a worse Return On Assets (-146.06%) than 84.29% of its industry peers.
  • The Return On Equity of CYCC (-177.03%) is worse than 64.88% of its industry peers.
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYCC Yearly ROA, ROE, ROICCYCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYCC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCC Yearly Profit, Operating, Gross MarginsCYCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CYCC Health Analysis

2.1 Basic Checks

  • CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CYCC has been increased compared to 1 year ago.
  • CYCC has more shares outstanding than it did 5 years ago.
  • CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYCC Yearly Shares OutstandingCYCC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
CYCC Yearly Total Debt VS Total AssetsCYCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • CYCC has an Altman-Z score of -136.20. This is a bad value and indicates that CYCC is not financially healthy and even has some risk of bankruptcy.
  • CYCC has a Altman-Z score of -136.20. This is amonst the worse of the industry: CYCC underperforms 96.86% of its industry peers.
  • There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -136.2
ROIC/WACCN/A
WACC9.66%
CYCC Yearly LT Debt VS Equity VS FCFCYCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • CYCC has a Current Ratio of 5.77. This indicates that CYCC is financially healthy and has no problem in meeting its short term obligations.
  • CYCC's Current ratio of 5.77 is fine compared to the rest of the industry. CYCC outperforms 61.55% of its industry peers.
  • A Quick Ratio of 5.77 indicates that CYCC has no problem at all paying its short term obligations.
  • The Quick ratio of CYCC (5.77) is better than 61.74% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
CYCC Yearly Current Assets VS Current LiabilitesCYCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CYCC Growth Analysis

3.1 Past

  • CYCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.85%, which is quite impressive.
  • The Revenue for CYCC has decreased by -87.50% in the past year. This is quite bad
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.35% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 385.15% on average over the next years. This is a very strong growth
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%

3.3 Evolution

CYCC Yearly Revenue VS EstimatesCYCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCC Yearly EPS VS EstimatesCYCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5K -10K -15K -20K -25K

More info and screens

Find the best growth stocksShow best growing peers

1

4. CYCC Valuation Analysis

4.1 Price/Earnings Ratio

  • CYCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CYCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCC Price Earnings VS Forward Price EarningsCYCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCC Per share dataCYCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CYCC's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYCC Dividend Analysis

5.1 Amount

  • CYCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYCC Fundamentals: All Metrics, Ratios and Statistics

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (9/11/2025, 8:00:01 PM)

After market: 6.4 +0.04 (+0.55%)

6.365

-0.4 (-5.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12
Earnings (Next)11-10
Inst OwnersN/A
Inst Owner Change6895.66%
Ins OwnersN/A
Ins Owner Change30.81%
Market Cap14.26M
Revenue(TTM)10.00K
Net Income(TTM)-6.43M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-50.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1425.76
P/FCF N/A
P/OCF N/A
P/B 3.93
P/tB 3.93
EV/EBITDA N/A
EPS(TTM)-122.02
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-3.9
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -136.2
F-Score3
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
EBIT growth 1Y48.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.04%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLACEL PHARMACEUTICALS INC / CYCC FAQ

What is the fundamental rating for CYCC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYCC.


What is the valuation status for CYCC stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLACEL PHARMACEUTICALS INC (CYCC). This can be considered as Overvalued.


How profitable is CYCLACEL PHARMACEUTICALS INC (CYCC) stock?

CYCLACEL PHARMACEUTICALS INC (CYCC) has a profitability rating of 0 / 10.


Can you provide the financial health for CYCC stock?

The financial health rating of CYCLACEL PHARMACEUTICALS INC (CYCC) is 6 / 10.